04, 2022 (GLOBE NEWSWIRE) - Synthetic Biologics, Inc. Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022 (NYSE American: SYN), a diversified clinical-stage company developing therapeutics desig 11, 2022 (GLOBE NEWSWIRE) - Synthetic Biologics, Inc. Prioritizing the advancement of novel oncolytic adenovirus (OV) platform-Cash balance as of Augof $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024-Conference call and webcast to be held today at 8:30 a.m. Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patient
05, 2022 (GLOBE NEWSWIRE) - Synthetic Biologics, Inc. Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck The most mentioned tickers in articles about SYN are MD.īelow are the latest news stories about SYNTHETIC BIOLOGICS INC that investors may wish to consider to help them evaluate SYN as an investment opportunity.Over the past 25 days, the trend for SYN's stories per day has been choppy and unclear.SYN's 30 day story count now stands at 2.
0 kommentar(er)
